{
    "Trade/Device Name(s)": [
        "Biolis 12i"
    ],
    "Submitter Information": "Tokyo Boeki Medisys Inc.",
    "510(k) Number": "K110520",
    "Predicate Device Reference 510(k) Number(s)": [
        "K042169",
        "K040958"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JGS",
        "CEM",
        "CGZ",
        "CFR",
        "JJE"
    ],
    "Summary Letter Date": "February 29, 2012",
    "Summary Letter Received Date": "March 6, 2012",
    "Submission Date": "January 6, 2012",
    "Regulation Number(s)": [
        "21CFR862.1665"
    ],
    "Regulation Name(s)": [
        "Sodium test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Sodium",
        "Potassium",
        "Chloride",
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Biolis 12i analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Photometry",
        "Ion-selective electrode (ISE)",
        "Indirect potentiometry",
        "Glucose hexokinase assay"
    ],
    "Methodologies": [
        "Spectrophotometric determination",
        "Direct quantitative measurement"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Instrument"
    ],
    "Document Summary": "FDA 510(k) summary for Biolis 12i automated clinical chemistry analyzer with optional ISE module for quantitative measurement of sodium, potassium, chloride, and glucose in serum",
    "Indications for Use Summary": "Intended for in vitro quantitative measurement of sodium, potassium, chloride, and glucose in serum for diagnosing and monitoring electrolyte and carbohydrate metabolism disorders; not for point-of-care testing",
    "fda_folder": "Clinical Chemistry"
}